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Abstract 
Background: Here, we isolated, expanded and functionally characterized regulatory T cells (Tregs) from patients with 
end stage kidney and liver disease, waiting for kidney/liver transplantation (KT/LT), with the aim to establish a suitable 
method to obtain large numbers of immunomodulatory cells for adoptive immunotherapy post-transplantation.
Methods: We first established a preclinical protocol for expansion/isolation of Tregs from peripheral blood of LT/
KT patients. We then scaled up and optimized such protocol according to good manufacturing practice (GMP) to 
obtain high numbers of purified Tregs which were phenotypically and functionally characterized in vitro and in vivo 
in a xenogeneic acute graft-versus-host disease (aGVHD) mouse model. Specifically, immunodepressed mice (NOD-
SCID-gamma KO mice) received human effector T cells with or without GMP-produced Tregs to prevent the onset of 
xenogeneic GVHD.
Results: Our small scale Treg isolation/expansion protocol generated functional Tregs. Interestingly, cryopreserva-
tion/thawing did not impair phenotype/function and DNA methylation pattern of FOXP3 gene of the expanded Tregs. 
Fully functional Tregs were also isolated/expanded from KT and LT patients according to GMP. In the mouse model, 
GMP Tregs from LT or KT patient proved to be safe and show a trend toward reduced lethality of acute GVHD.
Conclusions: These data demonstrate that expanded/thawed GMP-Tregs from patients with end-stage organ dis-
ease are fully functional in vitro. Moreover, their infusion is safe and results in a trend toward reduced lethality of acute 
GVHD in vivo, further supporting Tregs-based adoptive immunotherapy in solid organ transplantation.
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Background
Organ transplantation is the only curative treatment for 
patients affected by end-stage liver or kidney disease. 
Although immunosuppressive (IS) drugs have reduced 
the incidence of acute rejection and transplantation-
associated mortality, their administration is associated 
with major side effects, such as opportunistic infections, 
damage of transplanted organs and secondary cancer [1, 
2]. Therefore, new strategies to improve long-term graft 
survival while reducing/eliminating IS therapy and, ide-
ally, inducing immunological tolerance are needed.
Cellular therapy can improve the outcome of solid 
organ transplantation through anti-inflammatory effects 
and the induction of immune tolerance. T cell-mediated 
immunomodulation is one of the main mechanisms to 
maintain operational tolerance (withdrawal of immu-
nosuppressive drugs while maintaining normal graft 
function and histology) in  vivo. It is now accepted that 
regulatory T cells (Tregs), a subpopulation of T helper 
lymphocytes, are responsible for this immunomodu-
latory activity, as a result of their suppressive effects 
directly on effector T cells and on antigen presenting cells 
[3, 4]. Circulating Tregs constitutively express CD25 and 
FoxP3 and represent 5–10% of all peripheral CD4+ T 
cells [5, 6]. Tregs, which are fundamental for the mainte-
nance of immune homeostasis, demonstrated a key role 
for transplantation tolerance in animal models by impair-
ing the function of CD8+ T cells [7–10]. In humans, cell 
therapy with human Tregs for the induction of transplan-
tation tolerance represents a promising strategy [10, 11]. 
Indeed, clinical trials using this approach have already 
demonstrated that expanded polyclonal and antigen-
specific Tregs are safe and effective in the treatment of 
GVHD and Type 1 diabetes [12–17]. Conversely, very 
few results have been published on clinical trials test-
ing the efficacy of Tregs in solid organ transplantation 
[18, 19]. Moreover, isolated/ex vivo expanded Tregs have 
been only tested in animal models [20–22].
Here, we first established a preclinical protocol for 
expansion/isolation of Tregs from patients with end-
stage liver or kidney disease being in the waiting list for 
liver/kidney transplantation (LT/KT). We then scaled up 
and optimized such protocol according to good manufac-
turing practice (GMP) to obtain high numbers of puri-
fied Tregs which were tested in vitro and in a xenogeneic 
acute graft-versus-host disease (GVHD) mouse model.
Materials and methods
Patients
Peripheral blood (20–60  mL) was obtained from 14  LT 
and 9  KT patients. Patients characteristics are outlined 
in Table  1. Patient selection for GMP Tregs isolation/
expansion was based on the following inclusion criteria: 
(1) age ≥ 18 years; (2) diagnosis of end-stage kidney dis-
ease in waiting list for living donor kidney transplanta-
tion or diagnosis of end-stage liver disease in waiting list 
for liver transplantation. Exclusion criteria included: (1) 
HIV, HBV, HCV positivity; (2) syphilis antibody positiv-
ity; (3) combined transplant; (4) concurrent uncontrolled 
infection. Patient selection for in  vitro experiments 
were as above described except virus positivity. Periph-
eral blood (20–60 mL) and buffy-coat (30 mL) were also 
obtained from age and sex matched healthy controls. 
Human studies were conducted in accordance with the 
Declaration of Helsinki and approved by the local ethi-
cal Committee (232/2015/O/Tess by Investigation Drug 
Service, Azienda Ospedaliero-Universitaria di Bologna). 
Informed consent was obtained from all the subject prior 
to enrollment into the study.
Circulating Treg enumeration
Enumeration by flow cytometry of circulating Treg 
(CD4+CD25+CD127−FoxP3+) was carried out in the 
peripheral blood (PB) of selected KT and LT patients 
(n = 7 and n = 10, respectively) and of healthy controls 
(n = 9). The conjugated monoclonal antibodies used 
are shown in Additional file 1: Table S1. Surface marker 
staining was performed for 15 min at room temperature. 
For intracellular staining, anti-human FoxP3 (PCH101) 
Staining Set PE Kit was used (eBiosciences), according to 
the manufacturer’s instructions. Isotype control rat IgG2 
PE was used as a control. Briefly, cells were stained for 
surface markers CD4, CD25 and CD127, washed once 
in PBS and then fixed/permeabilized. After washing, 
cells were incubated with anti-human FoxP3 antibody 
for 30  min at 4  °C in the dark. A lysis buffer (Becton–
Dickinson) was used in order to lysate red blood cells. 
The phenotype of Tregs was analyzed by flow cytometry 
Table 1 Patients characteristics
NA not applicable, LT liver transplant, KT kidney transplant, CTR healthy control
KT LT CTR 
Total number 9 14 10
Sex (male/females) 3/6 8/6 5/5
Age (years; mean ± SD) 53 ± 13 61 ± 10 58 ± 12
Disease
 HCV/HBV liver cirrhosis N = 0 N = 8 NA
 Alcoholic liver cirrhosis N = 0 N = 3 NA
 Dysmetabolic liver cirrhosis N = 0 N = 2 NA
 Cryptogenetic liver cirrhosis N = 0 N = 1 NA
 Epatorenal polycystic disease N = 4 N = 0 NA
 End stage kidney disease N = 4 N = 0 NA
 Drug-induced tubulointerstitial nephritis N = 1 N = 0 NA
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FACSCantoII (Beckton Dickinson). Data were analyzed 
using the FACSDiva software (Becton–Dickinson). The 
percentage of positive cells was calculated by subtracting 
the value of the appropriate isotype controls. The abso-
lute number of positive cells per µL was calculated as fol-
lows: percentage of positive cells × white blood cell count 
(WBC)/100.
Tregs isolation and expansion
EDTA-anticoagulated peripheral blood (60 mL) was col-
lected from 4 LT patients, 2 KT patients and buffy-coat 
(30 mL) from 5 controls. Peripheral blood mononuclear 
cells (PBMC) were then isolated by Ficoll-Hystopaque 
density gradient centrifugation.
Isolation: freshly isolated CD8−CD25+ T cells were 
purified from PBMC by negative selection of CD8+ 
T cells followed by positive selection of CD25+ T cells 
using specific Miltenyi-Biotec Beads (CD8 microbeads 
human and CD25 microbeads II human) with Midi-
MACS separator and a purity (CD4+CD25+) of > 90%.
Expansion: freshly isolated cells were plated at 1 × 106/
mL cells and activated with anti-CD3/CD28 coated 
beads (Invitrogen, Paisley, UK; Miltenyi Biotech) at a 4:1 
bead:cell ratio at day 0 and then 1:1 bead:cell ratio weekly. 
Cells were expanded in culture media (TECSMacs GMP 
medium, Miltenyi Biotech) 5% human AB plasma con-
taining rapamycin (100 nM)  (Rapamune®, Wyeth, USA) 
for 21  days at 37  °C and 5%  CO2. IL-2 (1000  IU/mL, 
 Proleukin®, Novartis, UK) was added at day 4 post-acti-
vation and replenished every 2 days. Cells were restimu-
lated with beads every 7  days. After 21  days of culture, 
beads were magnetically removed and the cells washed in 
TECSMacs GMP medium. After washings, fresh beads, 
rapamycin and IL-2 were added. Expanded cells were 
used for further analysis at each time of re-stimulation up 
until day 21 of expansion.
Phenotypic characterization
Phenotypic characterization were performed on day 
0, 7, 14, 21 of cultures for ex  vivo expansion and after 
cryopreservation/thawing by flow cytometry as above 
described. Surface marker staining was performed in 
order to asses the content of Tregs and contaminant cells 
[monocytes (CD14+), B (CD19+) and T cells (CD8+), 
NK cells (CD56+), Th17 cells (CD196+CD161+)] present 
at each time point of culture (Additional file 1: Table S1).
FOXP3 promoter demethylation analysis
The highly conserved Treg-specific demethylation region 
(TSDR) within the human FOXP3 gene is demethyl-
ated exclusively on Tregs and not in any other blood-cell 
types. Specific DNA methylation of the Treg FOXP3 is 
referred to intron 1, as previously identified [23]. DNA 
methylation of FOXP3 gene (CNS2 region) of expanded 
cells (day + 21), either freshly isolated or after cryo-
preservation/thawing, was evaluated for a total of 6 sub-
jects (3 patients: 1 KT and 2 LT patients; and 3 controls). 
Genomic DNA was extracted from purified Tregs using 
the AllPrep DNA/RNA Mini Kit (QIAGEN, Hilden, 
Germany). 500  ng of DNA was bisulphite-converted 
using the EZ DNA Methylation Kit (Zymo Research 
Corporation, Orange, CA) according to manufacturer’s 
instructions, except for the thermal conditions of the 
conversion (21 cycles of 55  °C for 15 min and 95  °C for 
30  s). Bisulphite-treated DNA was eluted in 100  μL of 
water. DNA methylation analysis of the genomic region 
chrX:49,117,049–49,117,467 within FOXP3 gene body 
was performed by EpiTYPER assay (Sequenom, San 
Diego, CA), a quantitative method based on mass spec-
trometry that allows to evaluate methylation level at sin-
gle CpG sites/groups of adjacent CpG sites (CpG units). 
Ten ng of bisulphite-treated DNA were PCR-amplified 
and processed following manufacture’s instructions. The 
bisulphite specific primers were: FOXP3 forward, AGG 
AAG AGA GAT TTG TTT GGG GGT AGA GGA TTTA; 
FOXP3 reverse, CAG TAA TAC GAC TCA CTA TAG GGA 
GAA GGC TCA AAA AAA ACC AAA TCT TCA AAA CT.
For each gene, CpG sites with missing values in more 
than the 20% of the samples were removed, as well as 
samples with missing values in more than the 20% of 
CpG sites. The R package massArray was used to test if 
bisulphite conversion reaction run to completion [24]. 
For all samples analysed bisulphite conversion was from 
98.9 to 100%.
Mixed leukocyte reaction assay
The T cells were used as autologous responder cells for 
in  vitro suppression assays. The suppressive activity of 
freshly isolated and expanded cells were tested by co-cul-
turing CD8−CD25− T cells, labeled with 5 µM carboxy-
fluorescein succinimidyl ester (CFSE, Invitrogen), with 
serial dilutions of freshly isolated (CD8−CD25+ T cells) 
and ex vivo expanded autologous Tregs in the presence of 
CD3/CD28 GMP beads at ratio previously shown by us 
(in house experiments) to be effective in dose–response 
experiments (1:10 CD8−CD25− T cells to bead ratio) in 
RPMI-1640 medium containing 10% FBS, 1% penicilline/
streptomycine and l-glutamine (1%) for 5  days at 37  °C 
and 5%  CO2. Proliferation was analyzed by flow cytometry. 
The percentage of proliferative CD8−CD25− T cells in the 
absence of Tregs was taken as 100% proliferation.
GMP Treg isolation and expansion for in vivo experiments
The GMP manufacturing was performed in the Cell 
Factory of Fondazione IRCCS Ca’ Granda Ospedale 
Maggiore Policlinico, certified in compliance with 
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European GMP regulations by the Italian Drug Agency 
(authorization number aM-51/2018).
Steady state leukapheresis from 2 patients (1 KT and 
1 LT patient) were processed using GMP-compliant 
devices and reagents (Additional file  1: Figure  S1A). 
The subjects were evaluated for venous accesses suit-
ability. Leukapheresis was carried out by the COM.
TEC® (Fresenius Kabi AG, Bad Homburg, Germany) 
cell separator. The treatment of two blood volumes 
was set up as the procedure end-point. ACD-A was 
used for anticoagulation at a ratio of 1:14–1:13. For 
prophylaxis of citrate-related hypocalcemia, calcium 
gluconate was administered intravenously during the 
leukapheresis.
CD8−CD25+ cells were purified using the Clini-
MACS System (Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to GMP procedures and follow-
ing manufacturer’s instructions. Briefly, we performed 
a sequential two-step process based on the magnetic 
depletion of CD8+ T cells, followed by a positive 
selection of CD25+ cells after an over night storage, 
using monoclonal antibodies anti-CD8 (Miltenyi Bio-
tec) and anti-CD25 (Miltenyi Biotec), as described in 
the CliniMACS user manual for cell preparation, mag-
netic labelling, and selection.
Forty millions of CD8−CD25+ cells were expanded 
in  vitro in gas-permeable culture bags (MACS GMP 
Cell Expansion Bags and MACS GMP Cell Differen-
tiation Bags, Miltenyi Biotec) for 3 weeks in complete 
medium, consisting of TexMACS Medium (Miltenyi 
Biotec) supplemented with 100 nM rapamycin (Milte-
nyi Biotec), 5% allogeneic human heat-inactivated AB 
plasma, 500–1000  UI/mL IL-2 (Proleukin, Novartis 
Pharmaceuticals Canada Inc, Dorval, Quebec, Can-
ada). On day 0, 7 and 14, anti-CD3/CD28 beads 
(MACS GMP ExpAct Treg Beads, Miltenyi Biotec) 
were added at different beads:cells ratio 4:1, 1:1, 1:1 
respectively.
At day 21 all the cultured cells were collected and 
the beads were removed using the CliniMACS device, 
according to manufacturer’s instructions. Cells were 
counted by an automated and validated method (Nucle-
ocounter System, Chemometec, Allerød, Denmark). 
The Treg markers were evaluated by flow cytometry 
(BD FACSCanto II, BD Bioscience, San Jose, CA, USA) 
using the following antibodies: CD45 APC-H7 (BD Bio-
science), CD4 FITC (BD Bioscience), CD25 APC (BD 
Bioscience), CD127 PE-Cy7 (BD Bioscience) and FoxP3 
PE (eBioscience, San Diego, CA, USA).
Negative fraction (CD8−CD25− T cells) after GMP 
selection at day 0 and the final product after GMP 
expansion at day 21, were cryopreserved and thawed as 
above described.
Cryopreservation and thawing of freshly isolated 
and expanded cells
Freshly isolated fractions (CD8−CD25+ and CD8−
CD25− T cells) and expanded cells (after 7, 14 and 
21  days of expansion) were washed and cryopreserved 
with 10% DMSO (CRYOSERV, Mylan Institutionals, 
Canonsburg, PA, USA), 10% HSA (HAS; Kedrion, Lucca, 
Italy) in a saline solution (B. Braun, Melsungen, AG, Ger-
many) using a controlled-rate freezer. The frozen units 
were transferred and stored immediately to vapor-phase 
liquid nitrogen into dedicated tanks. All the cellular 
fractions were thawed at 37  °C and the viability, pheno-
type and suppressive function were assessed as above 
described.
Xenogeneic GVHD mouse model
NOD scid gamma (NSG) female mice (6–7 weeks of age) 
were purchased from Charles River (Calco, Italy). All 
animals were housed under specific pathogen-free con-
ditions in compliance with guidelines of the San Raffaele 
Institutional Animal Care and Use Committee (IACUC 
number: 632). Mice were maintained for at least 5  days 
in the animal facility for acclimatization before trans-
plantation. To promote the engraftment of transplanted 
cells injected intraperitoneally, all mice were conditioned 
with total body irradiation (1.75 cGy) on day 1. Of note, 
day 1 of the study is considered the day of transplant. All 
groups of mice, transplanted as well as control mice, were 
monitored for 7  weeks. Clinical signs of GVHD (e.g., 
hunched back, fur loss, skin inflammation) were moni-
tored daily. Body weight was monitored throughout the 
duration of the study. Animals showing marked clinical 
signs as of distress, loss of weight equal to or greater than 
20% of their starting weight were immediately sacrificed.
To establish whether the expanded Tregs could coun-
teract acute GVHD, a xeno-GvHD model was induced 
by intraperitoneally transfer of human autologous 
CD8−CD25− T cells from 1 LT and 1 KT patient into 
mice. Both CD8−CD25− T cells and expanded Tregs 
were injected within 30  min from thawing (Additional 
file  1: Figure  S1B). Specifically, human CD8−CD25− T 
cells (6 × 106) from LT or KT patients were injected with 
(simultaneous injection) or without autologous Treg 
(6 × 106) at a Treg: CD8−CD25− T cells ratio of 1:1. 
Timing of Treg infusion is crucial. In our model Tregs 
were infused at the time of T effector transplantation.
In vivo engraftment monitoring
To assess the in  vivo persistence of human cells, trans-
planted mice were bled 4 weeks after transplantation and 
sacrificed 7 weeks after transplantation. Phenotype anal-
ysis of injected cells and of peripheral blood at 4 weeks 
(± 3 days) after transplantation and of PB and spleen at 
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7  weeks (± 3  days) after transplantation was performed 
(Additional file  1: Figure  S1C). Following a Fc block-
ing step, cell surface staining was performed with anti-
mouse CD45 and anti-human CD4, CD3, CD25, FoxP3 
mAbs at 1:100 dilution in staining buffer (PBS, 2% FCS, 
0.1% NaN3) (list of mAbs is in Additional file 1: Table S1). 
To detect FoxP3, cells were treated and stained with the 
FoxP3 fixation/permeabilization kit according to the 
manufacturer’s instructions (eBioscience). Samples were 
acquired on a BD FACSCanto II flow cytometer. Manual 
analysis of flow cytometry data was performed with FCS 
Express V4 (DeNovo Software, Glendale, CA).
Statistical analysis
Statistical analyses were performed using GraphPad 
Prism (GraphPad Prism 5.0 soft-ware, SanDiego CA, 
USA), and data are presented as mean ± standard error 
of the mean (SEM). For all experiments involving mul-
tiple comparisons, analysis of variance (ANOVA) fol-
lowed by a Dunnett’s post hoc test was used. For those 
who involved comparisons between two groups, Stu-
dent’s t-test was used. The level of significance was set at 
p ≤ 0.05.
Results
Enumeration of circulating Treg from LT and KT patients
We firstly enumerated circulating CD4+CD25+CD127−
FoxP3+ Tregs in End-Stage Organ Disease patients and 
controls. The mean absolute numbers of circulating Tregs 
from LT (19.8 ± 10/mL) and KT (18.8 ± 7/mL) patients 
was not significantly different from that of healthy con-
trols (17 ± 4/mL) (p = NS; Additional file 1: Figure S2).
Tregs isolation, expansion, cryopreservation and thawing
Starting from 60  mL of PB (patients) and 30  mL of 
buffy-coat (healthy controls), CD8 depletion with 
subsequent CD25+ enrichment of PBMCs yielded 
a median of 3.7 × 106 nucleated cells (range 1.28–
8.8 × 106) in healthy controls, 1.47 × 106 nucleated 
cells (range 5.3 × 105–2.56 × 106) in LT patients and 
1.77 × 106 nucleated cells (range 8.5 × 105–2.7 × 106) 
in KT patients. The freshly isolated CD8−CD25+ 
T cells were 2.0 ± 1.2, 1.9 ± 1.3 and 2.6% ± 0.7 of the 
PBMCs, respectively, with no significant differences 
between patients/controls (p = NS) (data not shown). 
The Fig. 1a shows the gating strategy for identification 
of CD4+CD25+CD127−FoxP3+ Tregs which rep-
resented more than 80% of the cells (range 70–96%) 
within the CD8−CD25+ population. The median 
Treg purity (CD4+CD25+CD127−FoxP3+ cells) 
was 72% (range 50–84) and 55% (range 40–70) in LT 
and KT patients, respectively and 65% (range 54–80) 
in healthy controls (Fig.  1b). No significant difference 
was observed between patients and controls (p = NS). 
On day 0, contaminating cells in healthy controls were 
CD19+ B cells (16%, range 14.8–17), Th17 cells (4.7%, 
range 0.7–6.9) and CD14+ monocytes (6.3%, range 
0.8–11.4). In LT and KT patients, contaminating cells 
were mainly CD19+ B cells (6.8%, range 1.1–8.4; 5.4%, 
range 1.9–8.9, respectively) and Th17 cells (7.3%, range 
1.4–12.8; 11.8%, range 10.3–13.3, respectively). Natural 
Killer cells and monocytes content was always very low 
(below 1%) (Fig.  1c). By comparing patients and con-
trols, Th17 cells were significantly increased in KT cells 
as compared with LT or healthy controls (p ≤ 0.05 vs. 
LT patients; p ≤ 0.05 vs. healthy controls). In addition, 
CD19+ cells were significantly reduced in both patient 
groups as compared with the normal counterparts 
(p ≤ 0.05 for LT patients; p ≤ 0.05 for KT patients).
After 21  days, Tregs expanded a median of 197-folds 
(range 26–567) in LT patients, 266-folds (range 233–
300) in KT patients and 559-folds (range 342–826) in 
healthy controls (Fig.  2a). Differences between patients 
and controls were not statistically significant. Starting 
from freshly isolated 500 × 103 cells, the final yield was a 
median of 255 × 106 (range 171 × 106–413 × 106) nucle-
ated cells in healthy controls, 48 × 106 (range 30 × 106–
284 × 106) nucleated cells in LT patients and 133 (range 
116 × 106–150 × 106) nucleated cells in KT patients (data 
not shown). Treg purity (CD4+CD25+CD127−FoxP3+) 
increased significantly during expansion (Fig.  2b) in 
healthy donors and KT patients (p ≤ 0.05). Contami-
nating cells, namely B cells, Th17 cells and monocytes 
decreased below 1% in healthy controls and LT patients 
and below 3% in KT patients (Fig. 2c).
When cryopreserved/thawed 21  days expanded Tregs 
were analyzed, the mean percentage of viable cells was 
always more than 75% with no significant differences 
between patients and controls (Fig.  2d). The mean per-
centage of CD4+CD25+CD127−FoxP3+ cells was 
always > 80% (Fig. 2e).
When functional assays were performed, freshly iso-
lated cells (CD8−CD25+ T cells) from the three groups 
exerted a limited (healthy controls and LT patients) or 
poor (KT patients) suppressive effect toward autologous 
CD8−CD25− T cells proliferation in vitro (Fig. 3a). After 
21  days of in  vitro expansion, flow cytometry analysis 
demonstrated that, according to the increased T regula-
tory phenotype, Tregs from patients/controls had sig-
nificant suppressive activity (Fig.  3b), which was not 
modified by cryopreservation/thawing (Fig. 3c).
All together these data demonstrate that our small scale 
Treg isolation and expansion protocol from LT and KT 
patients lead to functional Tregs which are suitable for 
cell therapy. Moreover, cryopreservation/thawing does 
not impair phenotype/function of the expanded Tregs.
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FOXP3 methylation analysis
Figure 4a shows that in males the locus, which is localized 
on X chromosome, displayed low DNA methylation val-
ues (CpG sites ranging from 0.08 to 0.44). As expected, in 
females CpG sites had higher methylation values (ranging 
from 0.24 to 0.73) due to X chromosome inactivation We 
evaluated DNA methylation differences at day + 21 in 
freshly isolated and cryopreserved/thawed expanded cells 
in patients and controls separately using paired t-test. 
The large majority of CpG sites was not significant, and 
intra-individual difference between the two groups were 
generally small, spanning between − 0.13 and 0.23. The 
Fig. 1 Phenotype of the freshly isolated Tregs. a The gating strategy of Tregs identification after CD8 depletion and CD25 enrichment is shown. 
Dot plots depict the expression of CD25, CD127 and FoxP3. Interestingly, the majority of the freshly isolated cells expressed CD25. Dot plots are 
representative of 11 independent experiments from patients/controls. b Graph shows Treg purity, as percentage of CD4+CD25+CD127−FoxP3+ 
cells after isolation from PB of CTR, LT and KT patients. No significant difference was observed between patients and controls (p = NS). c Graph 
displays the percentages of contaminant cells in the freshly isolated product from CTR, LT and KT patients. Data are represented as mean ± SEM 
(*p < 0.05)
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Fig. 2 Phenotype of the in vitro expanded Tregs. a Tregs from CTR, LT and KT patients were expanded up to 21 days with IL-2 and rapamycin. Fold 
expansion of day 7, 14 and 21 was calculated as compared to day 0 seeded cells. b Graph shows the percentage of Treg (CD4+CD25+CD127−
FoxP3+) at each time point stimulation. Treg purity increased significantly during expansion in CTR and KT patients. c The graph shows the 
percentages of contaminant cells during the expansion period. The contaminant cells decreased below 1% in CTR and in LT patients and below 3% 
in KT patients at the end of expansion. d Viability of cryopreserved/thawed day 21 Tregs is shown. No significant difference was observed between 
patients and CTR (p = NS). e Phenotype of the cryopreserved/thawed day 21 Tregs is shown as mean percentages of CD4+CD25+CD127−FoxP3+ 
cells. The thawed Tregs were almost all FoxP3 positive in patients/CTR. No significant difference was observed between patients and controls 
(p = NS). Data are represented as mean ± SEM (*p < 0.05)
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only exception was the CpG_3 among controls (p-value: 
0.002), but, also in this case, the difference between the 
freshly isolated and the cryopreserved/thawed cells was 
small, ranging from 0.06 to 0.07 (Fig. 4b).
Collectively, these data suggest that the DNA meth-
ylation pattern of FOXP3 gene is substantially conserved 
after cryopreservation/thawing of ex  vivo expanded 
Tregs from LT and KT patients.
In vivo study
To investigate whether GMP expanded Tregs from 1 KT 
and 1 LT patient have inhibitory function  in vivo after 
thawing, we used a xenograft model of lethal GVHD. 
Specifically, irradiated NSG mice were injected with 
cryopreserved/thawed CD8−CD25− T cells either alone 
or in combination with autologous expanded cryopre-
served/thawed Tregs at 1:1 ratio to assess their ability 
to ameliorate GVHD (Additional file  1: Figure  S1). The 
rationale for this design is that early infusion of Tregs 
allows the cells to prevent T effector activation. After 
the immunomagnetic selection and expansion of 40 mil-
lions of freshly isolated CD8−CD25+ cells under GMP 
condition, we obtained 4.3 × 109 total cells (107.1-fold 
expansion) for the KT patient and 4.6 × 109 total cells 
(115.2-fold expansion) for the LT patient. Before expan-
sion the percentage of CD45+/CD4+/CD25+ cells was 
84.9% and 53.9% in KT and LT patient whereas, at the end 
of expansion, the percentage of CD45+/CD4+/CD25+ 
cells increased up to 98.3% and 89.2% respectively. At day 
21 CD45+/CD4+/CD25+/CD127−/FoxP3+ cells were 
79.2% and 84.4% respectively (data not shown).
Tregs were then thawed and characterized for 
the phenotype and in  vitro function. As shown in 
Fig.  5a, b, the thawed Tregs were more than 80% 
CD4+CD25+CD127−FoxP3+ and highly suppressive.
Mice receiving KT CD8−CD25− T cells lost weight 
and all succumbed to GVHD by day 40. In contrast, 
mice receiving KT CD8−CD25− T cells and autolo-
gous Tregs showed delayed disease-associated weight 
loss and slightly increased survival rate (by day 48 17% 
of mice receiving CD8−CD25− T cells with Tregs from 
the KT patient survived versus 0% for mice receiving 
CD8−CD25− T cells only; p = NS) (Fig.  6a, b). Similar 
results were obtained with cells from the LT patient: by 
day 48 58% of mice receiving CD8−CD25− T cells with 
Tregs from the LT patient survived versus 12.5% for mice 
receiving CD8−CD25− T cells only (p = NS; Fig. 6c, d).
To assess human cells engraftment in PB, animals 
were bled after 4/7 weeks and the percentages of human 
CD45+ cells in blood was determined (Fig. 7). The gating 
strategy is shown in Fig. 7a. No human CD45+ cells were 
identified in the PB of mice after infusion of Tregs alone 
from KT or LT patients. Conversely, a wide distribution 
of human CD45+ cells was observed in the PB of mice 
after transplant of CD8−CD25− T cells alone or CD8−
CD25− T cells plus Treg infusion (Fig. 7b, c).
To assess the biodistribution of infused human cells, 
spleen and PB cells of mice were stained with anti-
human CD45, CD3, CD4, FoxP3 monoclonal antibod-
ies after 7 weeks from transplant. The gating strategy is 
shown in Fig. 8a. By comparing PB and spleen, a higher 
mean percentage of human CD45+ cells was observed 
in the spleen versus PB of the mice after receiving 
CD8−CD25− T cells plus Treg of LT patients (p < 0.003; 
Fig.  8b). Of note, the majority of the human CD45+ 
cells were CD3+CD4+ in the blood/spleen of mice 
Fig. 3 Suppressive function of the in vitro expanded Tregs. 
The graphs show the mean percentages of proliferation of the 
CFSE-labelled autologous CD8−CD25− T cells in the presence 
of CD3/CD28 GMP beads and Tregs at different ratios. a MLR 
with freshly isolated Tregs (day 0). Freshly isolated Tregs from the 
three groups were limited (CTR and LT patients) or very poorly 
(KT patients) suppressive. b MLR with freshly isolated expanded 
Tregs (day 21). Expanded Tregs from patients/CTR had significant 
suppressive activity at 1:2 and 1:4 (Treg:CD8−CD25− T cells) 
ratio. c MLR with expanded and cryopreserved/thawed day 21 
Tregs. Cryopreservation/thawing did not significantly affects the 
suppressive activity of day 21 expanded Tregs of patients/CTR. Data 
are represented as mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001)
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after receiving KT or LT cells (Fig. 8c). Human FoxP3+ 
Tregs were identified in the CD3+CD4+ fraction of PB 
and spleen of the two groups of mice without differences 
between KT and LT cells (Fig. 8d).
Discussion
The use of Tregs for the treatment of GVHD and for 
inducing operational tolerance after solid organ trans-
plantation is a promising approach.
Here, we isolated, expanded and functionally charac-
terized Tregs from patients with end stage kidney and 
liver disease, with the aim to establish a suitable method 
to obtain immunomodulatory cells for adoptive immuno-
therapy post-transplantation.
We demonstrated that fully functional Tregs from 
patients in waiting list for solid organ transplantation 
can be isolated/expanded for clinical studies. These cel-
lular products show homogenous regulatory T cells 
characteristics with very low percentage of contaminat-
ing cells. Therefore, unwanted immune side effects are 
minimized. Of note, based on phenotype/function, the 
isolated/expanded Tregs from KT and LT patients are 
similar. Interestingly, our cryopreservation/thawing pro-
cedure allowed cell suspensions with phenotype/function 
and hypomethylation of the FOXP3 gene superimposable 
to that of the freshly isolated counterparts. This find-
ing challenges the notion that cryopreservation of Tregs 
products is detrimental for their function [25, 26].
Our freshly isolated cells from healthy donors and LT/
KT patients showed limited suppressive activity. This is 
in contrast with previous findings demonstrating 60–80% 
of suppressive activity by freshly isolated healthy donors 
cells, which were CD8−CD19−CD25+ cells [22] or 
CD8−CD25+ cells [27]. However, our results may be due 
(1) to the low purity of our freshly isolated cell suspen-
sion (CD8−CD25+ cells) and (2) to the fact that while 
our suppressive activity results were based on a 1:2 Treg/
Fig. 4 DNA methylation analysis of FOXP3 intron 1. a DNA methylation values of FOXP3 intron 1 in day + 21 freshly isolated GMP expanded 
Tregs from patients/healthy controls. b Differences in DNA methylation values of FOXP3 locus between day + 21 freshly isolated and day + 21 
cryopreserved/thawed GMP expanded Tregs. In both the panels blue and pink lines correspond to male and female subjects respectively, while 
continuous and dashed lines correspond to healthy controls and patients respectively
Fig. 5 GMP Treg expansion for the in vivo study: phenotype and 
function of cryopreserved/thawed day 21 expanded Tregs. a Graph 
shows the percentages of CD4+CD25+CD127−FoxP3+ Tregs of the 
LT and KT patient after thawing. Almost all cells were FoxP3 positive. 
b MLR assay is shown. Expanded Tregs from the LT or KT patient had 
significant suppressive activity at 1:2 and 1:4 ratios. (**p < 0.01)
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CD8−CD25− T cells working ratio, their ratio was 1:1 
Treg/Teff. Whether this results is also due to the fact that 
our freshly isolated healthy donors cells derive from 24 h 
aged buffy-coats remains a matter of speculation.
Safinia et  al. [10] firstly proposed a GMP production 
protocol to expand CD25+-enriched cells from PB in the 
presence of IL-2 and rapamycin to induce tolerance after 
liver transplantation. In their 36 days expansion protocol, 
multiple round of in  vitro Treg stimulation were neces-
sary to achieve clinically relevant Tregs number. In our 
protocol indeed, we obtained fully functional Tregs after 
21 days of expansion containing less than 1% of contami-
nating CD8+ effector cells. Expanded, cryopreserved 
and thawed Tregs remain hypomethylated at intron 1 of 
Fig. 6 In vivo study: injection of cryopreserved/thawed GMP day 21 Tregs from 1 KT and 1 LT patient in a xenogeneic GVHD murine model. a, 
c Show the percentage of body weight variation of mice receiving CD8−CD25− T cells only, GMP Tregs only or GMP Tregs plus CD8−CD25− T 
cells from KT and LT patients, respectively. Data are presented as means (KT/LT: CD8−CD25− T cells n = 7/8 mice; GMP Tregs n = 6/6 mice; GMP 
Tregs plus KT CD8−CD25− T cells n = 12/12 mice). b, d Show the survival rate of mice receiving CD8−CD25− T cells only, GMP Tregs only or GMP 
Tregs plus KT CD8−CD25− T cells from KT and LT patients, respectively. [Survival of mice receiving KT cells: statistically significant differences were 
observed only for Tregs versus CD8−CD25+ cells (p < 0.001) and Tregs versus CD8−CD25+cells+ Tregs (p < 0.01); survival of mice receiving LT cells: 
statistically significant differences were observed only for Tregs versus CD8−CD25+ cells (p < 0.05)]. Overall, mice receiving GMP Tregs plus CD8−
CD25− T cells showed a trend toward a time delay in body weight loss and survival as compared with mice injected with CD8−CD25− T cells only
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the FOXP3 locus, confirming their epigenetic stability. 
Functionally, Tregs showed suppressive function against 
autologous CD8−CD25− T cells.
Several human Treg products have been tested in ani-
mal models. However, previous data of Treg cell infu-
sion in non human primates report conflicts regarding 
the ability of the infused cells to induce transplant toler-
ance [28–30]. Thus, we decided to use a mouse model 
of GVHD in immunodepressed mice [i.e. NOD-SCID-
gamma KO (NSG) mice] receiving human effector T 
cells with or without GMP Tregs to prevent the onset 
of xenogeneic GVHD. In our mouse model, GMP Tregs 
from LT or KT patients proved to be safe and showed a 
trend toward reduced lethality of acute GVHD in  vivo. 
Interestingly, GMP Tregs from LT and KT patients did 
not induce xenogenic GVHD and did not expand as doc-
umented by the absence of Tregs in the PB and spleen 
of mice after 4 and 7 weeks from transplantation. This is 
probably due to the lack of human IL-2.
Nevertheless, our data are consistent with previ-
ous models of xenogeneic GVHD and Treg infu-
sion. The addition of CD25 expressing cells to human 
Fig. 7 In vivo study: human CD45+ cells engraftment in the xenogeneic GVHD murine model. Animals were bled after 4/7 weeks and the 
percentages of human CD45+ cells in blood was determined by flow cytometry. a Representative dot plots of human CD45+ cell engraftment 
at 4 weeks after transplant are shown. b, c No human CD45+ cells were identified in the PB of mice after infusion of Tregs alone from the KT or LT 
patient. Conversely, a wide distribution of human CD45+ cells were observed in the PB of mice after transplant of KT/LT CD8−CD25− T cells alone 
or CD8−CD25− T cells plus Treg infusion. In addition to individual data, mean values and SEM are shown
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PBMC showed the amelioration of xenogeneic GVHD, 
whereas the depletion of all CD25+ cells led to the 
development of lethal xenogeneic GVHD [31]. Also, 
in vitro expanded Tregs from human peripheral blood 
or cord blood were able to ameliorate or suppress 
xenogeneic GVHD [32, 33]. More recently, it has been 
reported that the infusion of polyclonal human Tregs 
improved murine xenogeneic chronic GVHD [34]. In 
addition, Del Papa et al. [22] used a similar methodol-
ogy (immune-magnetic Treg isolation and polyclonal 
expansion in the presence of CD3/CD28 beads, IL-2, 
and rapamycin for 19 days) achieving a median of 8.5-
fold expansion and maintaining FoxP3 expression over 
the culture period. NSG mice that received human leu-
kemic cells and expanded Tregs with conventional T 
cells were rescued from leukemia and survived without 
GVHD. Mice that received leukemic cells plus conven-
tional T cells died of severe GVHD within 70 days.
Conclusion
In summary, we demonstrated that expanded/thawed 
GMP Tregs from two different groups of patients with 
end-stage organ failure were fully functional in vitro and 
their infusion was safe and resulted in a trend toward 
reduced lethality of acute GVHD in vivo. These data fur-
ther support the expanded/thawed Tregs-based adoptive 
immunotherapy in solid organ transplantation.
Additional file
 Additional file 1: Table S1. Antibodies for flow cytometry. Figure S1. 
Design of the in vivo study. A. Steady state leukapheresis from 2 patients 
(1 KT and 1 LT patient) were processed using GMP-compliant devices 
and reagents. Tregs positive fraction (CD8−CD25+ cells) was purified 
using the CliniMACS System. Forty millions of CD8−CD25 + cells were 
Fig. 8 In vivo study: biodistribution of the infused GMP Tregs. Suspensions of spleen and PB after 7 weeks from transplant were stained with 
anti-human CD45, CD3, CD4, FoxP3 monoclonal antibodies and flow cytometry analysis was performed. a Depicts the gating strategy to identify 
the selected subpopulations. b–d Show the percentages of human CD45+, CD3+CD4+ and FoxP3+ Treg cells in the blood and spleen of mice 
after transplant of KT/LT CD8−CD25− T cells plus Treg. In addition to individual data, mean values and SEM are shown
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expanded in vitro for 3 weeks. At day 21 all the cultured cells were 
collected and the beads were removed using the CliniMACS device, 
according to manufacturer’s instructions. Negative fraction (CD8−CD25− 
T cells) after GMP selection at day 0 and the final product after GMP 
expansion at day 21 were cryopreserved and thawed as described in 
“Materials and methods” section. B. Irradiated NSG mice were infused 
with the KT or the LT CD8−CD25− T cells, either alone or in combina-
tion with autologous expanded Tregs at 1:1 ratio, to assess their ability to 
ameliorate GVHD. C. Mice were bled 4/7 weeks after transplantation and 
sacrificed 7 weeks after transplantation. FACS analysis of the injected cells 
(day 1), of PB (4 weeks ± 3 days after transplantation) and of PB and spleen 
(7 weeks ± 3 days after transplantation) was performed. Figure S2. Circu-
lating Tregs in KT and LT patients. Mean absolute number of circulating 
CD4+CD25+CD127−FoxP3+ Tregs from healthy controls and selected LT 
and KT patients (p = NS).
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